Day Zero Diagnostics


Contact Jong Lee
Title CEO & Co-Founder


Day Zero Diagnostics (DZD) is developing a new class of diagnostic that enables a physician to switch from broad spectrum antibiotic therapy to a targeted antibiotic in 5 hours rather than the 2-5 days that it typically takes today. Unlike other molecular diagnostics that can only detect a handful of specific targets, DZD uses the entire genomic sequence and our proprietary Keynome™ algorithm to identify a comprehensive range of bacterial pathogens and their resistance characteristics within hours.

The system includes a benchtop analyzer combined with proprietary single-use sample preparation cartridges. DZD starts with the same clinical samples that are typically sent to the microbiology lab. The system isolates and enriches bacterial DNA, enabling next generation sequencing without the need to wait for culture. The resulting genomes are then analyzed using a cloud-based analytics platform, allowing physicians to treat the patient with the right antibiotic in hours, rather than days.

DZD was founded in May 2016 and is currently a development stage company.   With $3.5M in total funds raised, DZD is targeting the delivery of a prototype in 2018.

Company News

Day Zero Diagnostics Wins $300K NIH Grant to Refine HAI Outbreak Analysis Service

DateDec 9, 2020
Infectious disease startup Day Zero Diagnostics last week received a $300,000 grant from the National Institutes of Health to further develop its nanopore sequencing-based technology for the analysis of healthcare-associated infection (HAI) outbreaks.
Read More →

Day Zero Diagnostics wins $6.2m from accelerator

DateMay 12, 2020
Boston-based Day Zero said in a news release that its system helps offer the most effective antibiotic treatment on the first day that patients are admitted to the hospital, rather than having them undergo multiple days of toxic broad-spectrum antibiotics to prevent septic shock.
Read More →

Day Zero Diagnostics: New Diagnostic Rapidly Identifies The Resistance Profile of Bacteria, Enabling Targeted Therapy Sooner

DateJan 17, 2018
At the 2017 meeting of AdvaMed, the medical device industry’s advocacy organization, young start-up Day Zero Diagnostics was chosen as this year’s MedTech Innovator Global Competition winner.

Day Zero Diagnostics is 2017 MedTech Innovator Global Competition Winner

DateSep 26, 2017
MedTech Innovator announced today Day Zero Diagnostics as the winner of its 2017 global competition. The Boston-based company was selected in a real-time vote by an audience of nearly 1,500 at The MedTech Conference powered by AdvaMed.